JP2005524631A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524631A5
JP2005524631A5 JP2003564020A JP2003564020A JP2005524631A5 JP 2005524631 A5 JP2005524631 A5 JP 2005524631A5 JP 2003564020 A JP2003564020 A JP 2003564020A JP 2003564020 A JP2003564020 A JP 2003564020A JP 2005524631 A5 JP2005524631 A5 JP 2005524631A5
Authority
JP
Japan
Prior art keywords
membered ring
independently selected
nitrogen
optionally substituted
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003564020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524631A (ja
JP4718118B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/002096 external-priority patent/WO2003064397A1/en
Publication of JP2005524631A publication Critical patent/JP2005524631A/ja
Publication of JP2005524631A5 publication Critical patent/JP2005524631A5/ja
Application granted granted Critical
Publication of JP4718118B2 publication Critical patent/JP4718118B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003564020A 2002-01-25 2003-01-23 プロテインキナーゼ阻害剤として有用なインダゾール化合物 Expired - Fee Related JP4718118B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35159702P 2002-01-25 2002-01-25
US60/351,597 2002-01-25
PCT/US2003/002096 WO2003064397A1 (en) 2002-01-25 2003-01-23 Indazole compounds useful as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006001918A Division JP2006176530A (ja) 2002-01-25 2006-01-06 プロテインキナーゼ阻害剤として有用なインダゾール化合物

Publications (3)

Publication Number Publication Date
JP2005524631A JP2005524631A (ja) 2005-08-18
JP2005524631A5 true JP2005524631A5 (enExample) 2005-12-22
JP4718118B2 JP4718118B2 (ja) 2011-07-06

Family

ID=27663008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003564020A Expired - Fee Related JP4718118B2 (ja) 2002-01-25 2003-01-23 プロテインキナーゼ阻害剤として有用なインダゾール化合物
JP2006001918A Pending JP2006176530A (ja) 2002-01-25 2006-01-06 プロテインキナーゼ阻害剤として有用なインダゾール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006001918A Pending JP2006176530A (ja) 2002-01-25 2006-01-06 プロテインキナーゼ阻害剤として有用なインダゾール化合物

Country Status (15)

Country Link
US (1) US7041687B2 (enExample)
EP (3) EP1467972A1 (enExample)
JP (2) JP4718118B2 (enExample)
KR (2) KR20100119902A (enExample)
CN (1) CN1812973B (enExample)
AR (1) AR038202A1 (enExample)
AU (1) AU2003212833C1 (enExample)
CA (1) CA2473986C (enExample)
IL (1) IL163117A (enExample)
MX (1) MXPA04007126A (enExample)
NO (1) NO328041B1 (enExample)
PL (1) PL371512A1 (enExample)
RU (1) RU2004125852A (enExample)
TW (1) TW200306819A (enExample)
WO (1) WO2003064397A1 (enExample)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217961B2 (en) * 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
CN1656079A (zh) * 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7169594B2 (en) * 2002-08-12 2007-01-30 Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
WO2005030776A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
AU2004284084A1 (en) 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
US7473783B2 (en) * 2003-12-17 2009-01-06 Sgx Pharmaceuticals, Inc. Bicyclic pyrazolo protein kinase modulators
FR2864084B1 (fr) 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
JP4734119B2 (ja) * 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
EP1718638A4 (en) * 2004-02-20 2009-04-22 Smithkline Beecham Corp NEW COMPOUNDS
US7378532B2 (en) 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
BRPI0513899A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de cinase heterocìclica de anel fundido
US20090029970A1 (en) * 2005-02-16 2009-01-29 Astellas Pharma Inc. Pain remedy containing rock inhibitor
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR060316A1 (es) 2006-01-17 2008-06-11 Vertex Pharma Azaindoles de utilidad como inhibidores de janus quinasas
GB0606429D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Organic compounds
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
CA2656618C (en) * 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2008061109A2 (en) * 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
WO2008070823A2 (en) 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
US8247421B2 (en) 2006-12-21 2012-08-21 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008094181A2 (en) * 2007-02-01 2008-08-07 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP2010522770A (ja) * 2007-03-29 2010-07-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害物質
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (es) * 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
ES2533557T3 (es) * 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
WO2009025478A1 (en) * 2007-08-17 2009-02-26 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
WO2009045479A1 (en) 2007-10-05 2009-04-09 Acucela Inc. Alkoxy compounds for disease treatment
MX2010007546A (es) 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
WO2009089459A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
US8993574B2 (en) 2008-04-24 2015-03-31 F2G Ltd Pyrrole antifungal agents
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP5502077B2 (ja) * 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
ES2566339T3 (es) * 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US20110129455A1 (en) * 2008-06-26 2011-06-02 Hong Lin Inhibitors of akt activity
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
US8697685B2 (en) * 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
MY161598A (en) * 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
HRP20141239T1 (xx) 2009-02-11 2015-03-13 Merck Patent Gmbh Novi amino azaheterocikliäśki karboksamidi
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
WO2010120854A1 (en) * 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
CN102459253B (zh) 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
GEAP202213376A (en) 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
US9023847B2 (en) 2009-08-07 2015-05-05 Merck Patent Gmbh Azaheterocyclic compounds
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
JP6014034B2 (ja) 2010-07-29 2016-10-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 環式アミンアザヘテロ環式カルボキサミド
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CN103201263A (zh) * 2010-09-08 2013-07-10 匹兹堡高等教育联邦体系大学 p53-Mdm2拮抗剂
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012065067A2 (en) 2010-11-12 2012-05-18 Georgetown University Immortalization of epithelial cells and methods of use
EP2643313B9 (en) 2010-11-24 2017-02-22 Merck Patent GmbH Quinazoline carboxamide azetidines
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
RS56534B1 (sr) 2011-09-12 2018-02-28 Merck Patent Gmbh Novi imidazol akmini kao modulatori aktivnosti kinaza
EA028057B1 (ru) 2011-09-12 2017-10-31 Мерк Патент Гмбх Производные аминопиримидина для применения в качестве модуляторов киназной активности
WO2013053051A1 (en) * 2011-10-12 2013-04-18 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
EA201791073A1 (ru) 2011-12-22 2017-09-29 Мерк Патент Гмбх Новые гетероциклические карбоксамиды в качестве модуляторов активности киназ
WO2013104829A1 (en) * 2012-01-13 2013-07-18 Medeia Therapeutics Ltd Novel arylamide derivatives having antiandrogenic properties
US8980934B2 (en) 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
WO2014056083A1 (en) * 2012-10-12 2014-04-17 University Health Network Kinase inhibitors and method of treating cancer with same
EP2920154B1 (en) 2012-11-16 2017-10-11 Merck Patent GmbH Novel imidazol-piperidinyl derivatives as modulators of kinase activity
CN105051043B (zh) 2012-11-16 2017-05-10 默克专利有限公司 用作激酶活性调节剂的新颖的杂环类衍生物
JP6290917B2 (ja) 2012-11-29 2018-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザキナゾリンカルボキサミド誘導体
KR20150124957A (ko) 2013-03-11 2015-11-06 메르크 파텐트 게엠베하 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체
EP2976080B1 (en) 2013-03-15 2019-12-25 Aerie Pharmaceuticals, Inc. Conjugates of isoquinoline compounds and prostaglandins
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
CN103570624B (zh) * 2013-08-06 2016-07-06 安徽世华化工有限公司 3-溴-5-硝基-1h-吲唑的合成工艺
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
NZ725361A (en) 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
CA2953524A1 (en) 2014-06-27 2015-12-30 The Regents Of The University Of California Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
AU2015348043B2 (en) 2014-11-21 2019-08-22 F2G Limited Antifungal agents
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
AU2016243750B2 (en) 2015-04-03 2022-02-03 Propagenix Inc. Ex vivo proliferation of epithelial cells
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
EP3347450B1 (en) 2015-09-11 2021-03-17 Propagenix Inc. Ex vivo proliferation of epithelial cells
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
EP3376870B1 (en) 2015-11-17 2021-08-11 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
JP7110232B2 (ja) * 2017-04-18 2022-08-01 イーライ リリー アンド カンパニー フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
WO2018234354A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH Novel substituted 3-indole and 3-indazole compounds as phosphodiesterase inhibitors
CN110869360B (zh) * 2017-07-12 2023-12-15 百时美施贵宝公司 作为rock抑制剂的苯乙酰胺类
WO2019018855A1 (en) 2017-07-21 2019-01-24 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
CA3070112A1 (en) * 2017-07-21 2019-01-24 Kadmon Corporation, Llc Inhibitors of rho associated coiled-coil containing protein kinase
WO2019161157A1 (en) 2018-02-16 2019-08-22 Constellation Pharmceuticals, Inc. P300/cbp hat inhibitors
FI3752497T3 (fi) * 2018-02-16 2024-09-25 Constellation Pharmaceuticals Inc P300/cbp-hat:n estäjiä
CA3107502A1 (en) 2018-08-20 2020-02-27 Chengkang ZHANG Epithelial cell spheroids
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CA3149095A1 (en) * 2019-07-29 2021-02-04 Constellation Pharmaceuticals, Inc. Alpha-amino amide compounds for use in treating neurological disorders
BR112022001054A2 (pt) * 2019-08-21 2022-03-15 Kalvista Pharmaceuticals Ltd Inibidores enzimáticos
AU2020340427A1 (en) 2019-08-29 2022-03-31 Hibercell, Inc. PERK inhibiting compounds
EP3845276B1 (en) * 2019-12-31 2025-01-29 Industrial Technology Research Institute Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and use of the same
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
EP4142879A1 (en) 2020-04-27 2023-03-08 Novartis AG Methods and compositions for ocular cell therapy
JP2023551408A (ja) 2020-11-16 2023-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング がん処置のためのキナーゼインヒビター組み合わせ
US20240425816A1 (en) 2021-10-18 2024-12-26 Evia Life Sciences Inc. Compositions and methods of use thereof for treating liver fibrosis
JP2024539220A (ja) 2021-10-22 2024-10-28 エヴィア ライフ サイエンシズ インコーポレイテッド 細胞外小胞を作製するための方法、組成物、およびその使用方法
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途
CN116715634B (zh) * 2023-06-12 2025-11-21 北京新源医疗有限责任公司 一种化合物、药物组合物及在制备血管舒张药物中的应用
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用
CN117229217A (zh) * 2023-09-14 2023-12-15 常州大学 一种肾上腺素受体功能活性的别构调节剂及其制备方法和应用
WO2025088534A1 (en) * 2023-10-27 2025-05-01 Dong-A St Co., Ltd. Bicyclic heterocycle compounds as tead inhibitor
CN117603084A (zh) * 2023-12-18 2024-02-27 江苏瑞思坦生物科技有限公司 肽酶神经溶素增强剂及其制备方法和应用
CN121471116A (zh) * 2026-01-08 2026-02-06 首都医科大学附属北京胸科医院 含有磺酰基的化合物及其制备和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640715B2 (enExample) 1974-04-01 1981-09-22
WO1990002744A1 (en) 1988-09-15 1990-03-22 The Upjohn Company In position 3 substituted-5-beta-amidomethyl-oxazolidin-2-ones
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2002255263B2 (en) * 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2005524631A5 (enExample)
RU2004125852A (ru) Имидазольные соединения, применяемые в качестве ингибиторов протеинкиназы
RU2410378C2 (ru) Сульфоксиминзамещенные пиримидины в качестве ингибиторов cdk и/или vegf, их получение и применение в качестве лекарственных средств
JP5763834B2 (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン塩類
JP2021063120A5 (enExample)
JP2010510215A5 (enExample)
JP2010513285A5 (enExample)
RU2014110623A (ru) Пирролопиразиновые ингибиторы киназы
JP2013506715A5 (enExample)
JP2011509309A5 (enExample)
JP2012524053A5 (enExample)
JP2020514316A5 (enExample)
JP2014077003A5 (enExample)
JPWO2021188769A5 (enExample)
JP2016525104A5 (enExample)
JP2007515419A5 (enExample)
JP2019520344A5 (enExample)
JP2010510216A5 (enExample)
JP2010540649A5 (enExample)
JP2020534266A5 (enExample)
CN1533293A (zh) 包含埃坡霉素的组合及其药学应用
JPWO2022125790A5 (enExample)
RU2004126637A (ru) Производные порфиринплатины, терапевтические активное соединение для получения средства для лечения опухолей, лекарственное средство и способ получения указанного средства
KR920016418A (ko) Nmda 길항제
CN1367690A (zh) 使用五氟苯磺酰胺的综合疗法